Histone deacetylase (HDAC) inhibition results in increases and normalization in gene transcription. EnVivo is currently investigating how this unique activity can have an important impact on CNS diseases that display abnormalities in this gene transcription, for example Parkinson's disease and certain orphan indications.
EnVivo’s EVP-0334 represents a first-in-class, CNS-penetrant HDAC inhibitor in development expressly for CNS diseases that has successfully and safely completed Phase 1 clinical trials.
EnVivo has received a research grant from the Michael J. Fox Foundation for Parkinson’s Research to study EVP-0334 in two preclinical models and is also exploring this program in animal models with various neurodegenerative indications, including several orphan indications. EnVivo expects to select a clinical indication and move EVP-0334 forward in the clinic later this year.